Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency

Metastatic dissemination in breast cancer patients occurs early in malignant transformation, raising questions about how disseminated cancer cells (DCC) progress at distant sites. Here, the authors show that DCCs in bone marrow are activated via IL6-trans-signaling and thereby acquire stemness trait...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Melanie Werner-Klein, Ana Grujovic, Christoph Irlbeck, Milan Obradović, Martin Hoffmann, Huiqin Koerkel-Qu, Xin Lu, Steffi Treitschke, Cäcilia Köstler, Catherine Botteron, Kathrin Weidele, Christian Werno, Bernhard Polzer, Stefan Kirsch, Miodrag Gužvić, Jens Warfsmann, Kamran Honarnejad, Zbigniew Czyz, Giancarlo Feliciello, Isabell Blochberger, Sandra Grunewald, Elisabeth Schneider, Gundula Haunschild, Nina Patwary, Severin Guetter, Sandra Huber, Brigitte Rack, Nadia Harbeck, Stefan Buchholz, Petra Rümmele, Norbert Heine, Stefan Rose-John, Christoph A. Klein
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2020
Sujets:	Science Q
Accès en ligne:	https://doaj.org/article/852fb79d2cfa456b923be4f3ce115b15
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency

Documents similaires